{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T08:12:12Z","timestamp":1794989532641,"version":"4.9.1"},"reference-count":92,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"publisher","award":["273672"],"award-info":[{"award-number":["273672"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"publisher","award":["198016"],"award-info":[{"award-number":["198016"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013955","name":"Astellas Pharma BV","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013955","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021821","name":"Oncode Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021821","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006044","name":"Astellas Pharma Europe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006044","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002999","name":"Ministerie van Volksgezondheid, Welzijn en Sport","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002999","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Research Council of Finland","doi-asserted-by":"publisher","award":["349314"],"award-info":[{"award-number":["349314"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"Dutch Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["PC180367"],"award-info":[{"award-number":["PC180367"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.xcrm.2025.102215","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T10:39:48Z","timestamp":1751452788000},"page":"102215","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Epigenetic profiling identifies markers of endocrine resistance and therapeutic options for metastatic castration-resistant prostate cancer"],"prefix":"10.1016","volume":"6","author":[{"given":"Tesa M.","family":"Severson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Minnee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karianne","family":"Schuurman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly M.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisha G.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sini","family":"Hakkola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee","family":"Menezes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Gregoricchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongsoo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"Kneppers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Linder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzan","family":"Stelloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cor","family":"Lieftink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiel S.","family":"van der Heijden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matti","family":"Nykter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"van der Noort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Jenster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert JLH","family":"van Leenders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Pomerantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew L.","family":"Freedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roderick L.","family":"Beijersbergen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Urbanucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lodewyk","family":"Wessels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Corey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Prekovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9823-7289","authenticated-orcid":false,"given":"Wilbert","family":"Zwart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andries M.","family":"Bergman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2025.102215_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.xcrm.2025.102215_bib2","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur. Urol."},{"key":"10.1016\/j.xcrm.2025.102215_bib3","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1001\/jama.294.4.433","article-title":"Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy","volume":"294","author":"Freedland","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.xcrm.2025.102215_bib4","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.urology.2006.03.075","article-title":"Use of different definitions of biochemical failure after external beam radiotherapy changes conclusions about relative treatment efficacy for localized prostate cancer","volume":"68","author":"Kupelian","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.xcrm.2025.102215_bib5","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1097\/01.ju.0000134888.22332.bb","article-title":"Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results","volume":"172","author":"Roehl","year":"2004","journal-title":"J. Urol."},{"key":"10.1016\/j.xcrm.2025.102215_bib6","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/ncpuro1296","article-title":"Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion","volume":"6","author":"Harris","year":"2009","journal-title":"Nat. Clin. Pract. Urol."},{"key":"10.1016\/j.xcrm.2025.102215_bib7","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1158\/1535-7163.MCT-15-0892","article-title":"The Effect of F877L and T878A Mutations on Androgen Receptor Response to Enzalutamide","volume":"15","author":"Prekovic","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.xcrm.2025.102215_bib8","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/ng.3419","article-title":"The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis","volume":"47","author":"Pomerantz","year":"2015","journal-title":"Nat. Genet."},{"key":"10.1016\/j.xcrm.2025.102215_bib9","doi-asserted-by":"crossref","first-page":"4900","DOI":"10.1038\/s41467-018-07270-2","article-title":"Integrative epigenetic taxonomy of primary prostate cancer","volume":"9","author":"Stelloo","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102215_bib10","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.cell.2008.01.018","article-title":"FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription","volume":"132","author":"Lupien","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2025.102215_bib11","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.cell.2009.04.056","article-title":"Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer","volume":"138","author":"Wang","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2025.102215_bib12","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.cell.2015.08.008","article-title":"Architectural and Functional Commonalities between Enhancers and Promoters","volume":"162","author":"Kim","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2025.102215_bib13","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/nrg3682","article-title":"Transcriptional enhancers: from properties to genome-wide predictions","volume":"15","author":"Shlyueva","year":"2014","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.xcrm.2025.102215_bib14","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2025.102215_bib15","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2025.102215_bib16","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1530\/ERC-18-0289","article-title":"Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond","volume":"26","author":"Linder","year":"2018","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.xcrm.2025.102215_bib17","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.ccell.2019.10.005","article-title":"Cistrome Partitioning Reveals Convergence of Somatic Mutations and Risk Variants on Master Transcription Regulators in Primary Prostate Tumors","volume":"36","author":"Mazrooei","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2025.102215_bib18","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/s41588-020-0664-8","article-title":"Prostate cancer reactivates developmental epigenomic programs during metastatic progression","volume":"52","author":"Pomerantz","year":"2020","journal-title":"Nat. Genet."},{"key":"10.1016\/j.xcrm.2025.102215_bib19","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.15252\/emmm.201505424","article-title":"Androgen receptor profiling predicts prostate cancer outcome","volume":"7","author":"Stelloo","year":"2015","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.xcrm.2025.102215_bib20","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1002\/1878-0261.12923","article-title":"Epigenetic and transcriptional analysis reveals a core transcriptional program conserved in clonal prostate cancer metastases","volume":"15","author":"Severson","year":"2021","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.xcrm.2025.102215_bib21","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/onc.2017.330","article-title":"Endogenous androgen receptor proteomic profiling reveals genomic subcomplex involved in prostate tumorigenesis","volume":"37","author":"Stelloo","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.xcrm.2025.102215_bib22","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/nature10730","article-title":"Differential oestrogen receptor binding is associated with clinical outcome in breast cancer","volume":"481","author":"Ross-Innes","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102215_bib23","doi-asserted-by":"crossref","first-page":"D280","DOI":"10.1093\/nar\/gkac968","article-title":"SEdb 2.0: a comprehensive super-enhancer database of human and mouse","volume":"51","author":"Wang","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2025.102215_bib24","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1038\/s41467-021-21860-7","article-title":"A noncanonical AR addiction drives enzalutamide resistance in prostate cancer","volume":"12","author":"He","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102215_bib25","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.neo.2014.09.001","article-title":"The long non-coding RNA PCAT-1 promotes prostate cancer cell proliferation through cMyc","volume":"16","author":"Prensner","year":"2014","journal-title":"Neoplasia"},{"key":"10.1016\/j.xcrm.2025.102215_bib26","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1038\/onc.2009.496","article-title":"Wnt5a signaling is involved in the aggressiveness of prostate cancer and expression of metalloproteinase","volume":"29","author":"Yamamoto","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.xcrm.2025.102215_bib27","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/pros.23313","article-title":"LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer Therapeutics","volume":"77","author":"Nguyen","year":"2017","journal-title":"Prostate"},{"key":"10.1016\/j.xcrm.2025.102215_bib28","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1038\/s41467-021-25624-1","article-title":"Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse","volume":"12","author":"Taavitsainen","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102215_bib29","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nmeth.4556","article-title":"GIGGLE: a search engine for large-scale integrated genome analysis","volume":"15","author":"Layer","year":"2018","journal-title":"Nat. Methods"},{"key":"10.1016\/j.xcrm.2025.102215_bib30","doi-asserted-by":"crossref","first-page":"D658","DOI":"10.1093\/nar\/gkw983","article-title":"Cistrome Data Browser: a data portal for ChIP-Seq and chromatin accessibility data in human and mouse","volume":"45","author":"Mei","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2025.102215_bib31","doi-asserted-by":"crossref","first-page":"D729","DOI":"10.1093\/nar\/gky1094","article-title":"Cistrome Data Browser: expanded datasets and new tools for gene regulatory analysis","volume":"47","author":"Zheng","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2025.102215_bib32","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.ccell.2017.10.008","article-title":"Aberrant Activation of a Gastrointestinal Transcriptional Circuit in Prostate Cancer Mediates Castration Resistance","volume":"32","author":"Shukla","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2025.102215_bib33","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.20183","article-title":"Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancer","volume":"6","author":"Li","year":"2017","journal-title":"eLife"},{"key":"10.1016\/j.xcrm.2025.102215_bib34","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1158\/1078-0432.CCR-17-0989","article-title":"The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy","volume":"24","author":"Puhr","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102215_bib35","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.27861","article-title":"Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer","volume":"6","author":"Shah","year":"2017","journal-title":"eLife"},{"key":"10.1016\/j.xcrm.2025.102215_bib36","doi-asserted-by":"crossref","first-page":"29782","DOI":"10.18632\/oncotarget.4927","article-title":"FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer","volume":"6","author":"Jones","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.xcrm.2025.102215_bib37","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/sj.bjc.6690684","article-title":"Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system","volume":"81","author":"Culig","year":"1999","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.xcrm.2025.102215_bib38","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2159-8290.CD-15-1263","article-title":"The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer","volume":"7","author":"Bishop","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2025.102215_bib39","doi-asserted-by":"crossref","first-page":"26259","DOI":"10.18632\/oncotarget.8456","article-title":"Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer","volume":"7","author":"Kregel","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.xcrm.2025.102215_bib40","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1158\/1541-7786.MCR-18-1231","article-title":"The Pioneering Role of GATA2 in Androgen Receptor Variant Regulation Is Controlled by Bromodomain and Extraterminal Proteins in Castrate-Resistant Prostate Cancer","volume":"17","author":"Chaytor","year":"2019","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102215_bib41","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/pros.23467","article-title":"Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer","volume":"78","author":"McLeod","year":"2018","journal-title":"Prostate"},{"key":"10.1016\/j.xcrm.2025.102215_bib42","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/nm.3830","article-title":"Targeting the MLL complex in castration-resistant prostate cancer","volume":"21","author":"Malik","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2025.102215_bib43","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1021\/acsmedchemlett.0c00462","article-title":"Discovery of Highly Selective and Potent HDAC3 Inhibitors Based on a 2-Substituted Benzamide Zinc Binding Group","volume":"11","author":"Liu","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.xcrm.2025.102215_bib44","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102215_bib45","first-page":"5165","article-title":"Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo","volume":"60","author":"Butler","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102215_bib46","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1158\/1535-7163.MCT-06-0144","article-title":"Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation","volume":"6","author":"Marrocco","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.xcrm.2025.102215_bib47","first-page":"64","article-title":"HDAC inhibitors with potential to overcome drug resistance in castration-resistant prostate cancer","volume":"5","author":"Biersack","year":"2022","journal-title":"Cancer Drug Resist."},{"key":"10.1016\/j.xcrm.2025.102215_bib48","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.cell.2013.11.012","article-title":"Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade","volume":"155","author":"Arora","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2025.102215_bib49","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.1038\/s41467-021-24537-3","article-title":"Glucocorticoid receptor triggers a reversible drug-tolerant dormancy state with acquired therapeutic vulnerabilities in lung cancer","volume":"12","author":"Prekovic","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102215_bib50","doi-asserted-by":"crossref","first-page":"28900","DOI":"10.1074\/jbc.M113.505115","article-title":"Class I lysine deacetylases facilitate glucocorticoid-induced transcription","volume":"288","author":"Kadiyala","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.xcrm.2025.102215_bib51","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/s41467-020-14644-y","article-title":"Androgen receptor-binding sites are highly mutated in prostate cancer","volume":"11","author":"Morova","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102215_bib52","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/s41467-020-14318-9","article-title":"Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer","volume":"11","author":"Zhou","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102215_bib53","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.cell.2018.06.039","article-title":"Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer","volume":"174","author":"Quigley","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2025.102215_bib54","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.cell.2018.05.037","article-title":"A Somatically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver in Advanced Prostate Cancer","volume":"174","author":"Takeda","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2025.102215_bib55","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1158\/2159-8290.CD-13-0142","article-title":"An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide)","volume":"3","author":"Korpal","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2025.102215_bib56","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1038\/sj.onc.1209424","article-title":"Androgen receptor mutation (T877A) promotes prostate cancer cell growth and cell survival","volume":"25","author":"Sun","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.xcrm.2025.102215_bib57","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abe2261","article-title":"Posttranslational regulation of FOXA1 by Polycomb and BUB3\/USP7 deubiquitin complex in prostate cancer","volume":"7","author":"Park","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.xcrm.2025.102215_bib58","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/s41588-020-0681-7","article-title":"Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancer","volume":"52","author":"Gao","year":"2020","journal-title":"Nat. Genet."},{"key":"10.1016\/j.xcrm.2025.102215_bib59","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/0008-5472.CAN-08-2216","article-title":"Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer","volume":"69","author":"Welsbie","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102215_bib60","doi-asserted-by":"crossref","first-page":"6623","DOI":"10.1158\/1078-0432.CCR-19-1305","article-title":"Phase I\/Ib Study of Pembrolizumab Plus Vorinostat in Advanced\/Metastatic Non-Small Cell Lung Cancer","volume":"25","author":"Gray","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102215_bib61","doi-asserted-by":"crossref","first-page":"5541","DOI":"10.1002\/cncr.24597","volume":"115","author":"Bradley","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.xcrm.2025.102215_bib62","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1158\/1078-0432.CCR-18-1589","article-title":"Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer","volume":"25","author":"Ferrari","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102215_bib63","doi-asserted-by":"crossref","first-page":"e2136","DOI":"10.1002\/onco.13957","article-title":"Phase I Study of Entinostat in Combination with Enzalutamide for Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer","volume":"26","author":"Lin","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.xcrm.2025.102215_bib64","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1158\/1078-0432.CCR-21-3762","article-title":"Detecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation Analysis","volume":"28","author":"Berchuck","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102215_bib65","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-50220-1","article-title":"Drivers of AR indifferent anti-androgen resistance in prostate cancer cells","volume":"9","author":"Handle","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.xcrm.2025.102215_bib88","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1530\/JME-18-0226","article-title":"PEG10 is associated with treatment-induced neuroendocrine prostate cancer","volume":"63","author":"Kim","year":"2019","journal-title":"J. Mol. Endocrinol."},{"key":"10.1016\/j.xcrm.2025.102215_bib66","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","article-title":"Fast and accurate short read alignment with Burrows-Wheeler transform","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2025.102215_bib67","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","article-title":"The Sequence Alignment\/Map format and SAMtools","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2025.102215_bib68","doi-asserted-by":"crossref","DOI":"10.1186\/gb-2008-9-9-r137","article-title":"Model-based analysis of ChIP-Seq (MACS)","volume":"9","author":"Zhang","year":"2008","journal-title":"Genome Biol."},{"key":"10.1016\/j.xcrm.2025.102215_bib69","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1534\/g3.113.008680","article-title":"Large-scale quality analysis of published ChIP-seq data","volume":"4","author":"Marinov","year":"2014","journal-title":"G3 (Bethesda)"},{"key":"10.1016\/j.xcrm.2025.102215_bib70","doi-asserted-by":"crossref","first-page":"W160","DOI":"10.1093\/nar\/gkw257","article-title":"deepTools2: a next generation web server for deep-sequencing data analysis","volume":"44","author":"Ramirez","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2025.102215_bib71","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/bioinformatics\/btaa692","article-title":"pyGenomeTracks: reproducible plots for multivariate genomic datasets","volume":"37","author":"Lopez-Delisle","year":"2021","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2025.102215_bib72","series-title":"R package: hexbin","author":"Carr","year":"2024"},{"key":"10.1016\/j.xcrm.2025.102215_bib73","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1093\/bioinformatics\/btv145","article-title":"ChIPseeker: an R\/Bioconductor package for ChIP peak annotation, comparison and visualization","volume":"31","author":"Yu","year":"2015","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2025.102215_bib74","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1093\/bioinformatics\/btq033","article-title":"BEDTools: a flexible suite of utilities for comparing genomic features","volume":"26","author":"Quinlan","year":"2010","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2025.102215_bib75","series-title":"R package: GeneOverlap: Test and visualize gene overlaps","author":"Shen","year":"2025"},{"key":"10.1016\/j.xcrm.2025.102215_bib76","series-title":"ggplot2: Elegant Graphics for Data Analysis","author":"Wickham","year":"2016"},{"key":"10.1016\/j.xcrm.2025.102215_bib77","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","article-title":"Integrated analysis of multimodal single-cell data","volume":"184","author":"Hao","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2025.102215_bib78","unstructured":"Kassambara, A. (2023). R package: ggpubr: \u2018ggplot2' Based Publication Ready Plots.URL: https:\/\/ggplot2.tidyverse.org."},{"key":"10.1016\/j.xcrm.2025.102215_bib79","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1101\/gr.107524.110","article-title":"The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data","volume":"20","author":"McKenna","year":"2010","journal-title":"Genome Res."},{"key":"10.1016\/j.xcrm.2025.102215_bib80","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1093\/bioinformatics\/btz720","article-title":"ChIPseqSpikeInFree: a ChIP-seq normalization approach to reveal global changes in histone modifications without spike-in","volume":"36","author":"Jin","year":"2020","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2025.102215_bib81","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/s41587-019-0201-4","article-title":"Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype","volume":"37","author":"Kim","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xcrm.2025.102215_bib82","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","article-title":"HTSeq--a Python framework to work with high-throughput sequencing data","volume":"31","author":"Anders","year":"2015","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2025.102215_bib83","doi-asserted-by":"crossref","first-page":"W488","DOI":"10.1093\/nar\/gkaa216","article-title":"SynergyFinder 2.0: visual analytics of multi-drug combination synergies","volume":"48","author":"Ianevski","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2025.102215_bib84","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102215_bib85","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-Update and clarification: From the RECIST committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.xcrm.2025.102215_bib86","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1159\/000448219","article-title":"Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer","volume":"91","author":"Badrising","year":"2016","journal-title":"Oncology"},{"key":"10.1016\/j.xcrm.2025.102215_bib87","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1016\/S1470-2045(19)30688-6","article-title":"Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial","volume":"20","author":"Khalaf","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2025.102215_bib89","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/s41467-018-02856-2","article-title":"Characterizing steroid hormone receptor chromatin binding landscapes in male and female breast cancer","volume":"9","author":"Severson","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102215_bib90","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.201800115","article-title":"Optimized ChIP-seq method facilitates transcription factor profiling in human tumors","volume":"2","author":"Singh","year":"2019","journal-title":"Life Sci. Alliance"},{"key":"10.1016\/j.xcrm.2025.102215_bib91","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nbt1186","article-title":"Statistical practice in high-throughput screening data analysis","volume":"24","author":"Malo","year":"2006","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xcrm.2025.102215_bib92","series-title":"Mixed-Effects Models in S and S-PLUS","author":"Pinheiro","year":"2006"}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125002885?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125002885?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T21:42:01Z","timestamp":1762638121000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379125002885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":92,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S2666379125002885"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102215","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.02.24.23286403","asserted-by":"object"}]},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epigenetic profiling identifies markers of endocrine resistance and therapeutic options for metastatic castration-resistant prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102215","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102215"}}